Articles and Publications with Colored Text are hyperlinked to the publishers’ sites. All other articles can often be found with a search of the title. Publishers regularly move and archive materials making links to older articles obsolete. Contact us directly if you want any specific article.
2021
A series of four articles outlining the principles of ESCP Analysis – Efficacy. Safety, Convenience and Pricing were published in the first half of 2021. These article provide a quick and dirty way to assess product opportunity in the context of a competitive marketplace.
2021-03: “ESCP, Estimating Product Performance Part 1 – Playground Physics”. Drug Development & Delivery March 2021 Vol 21 No 2, p. 69 (link to issue)
2021-04: “ESCP, Estimating Product Performance Part 2 – Choosing a Seesaw”. Drug Development & Delivery April 2021 Vol 21 No 3, p. 44 (link to issue)
2021-05: “ESCP, Estimating Product Performance Part 3 – Mind the Axle”. Drug Development & Delivery May 2021 Vol 21 No 4, p. 39 (link to issue)
2021-06: “ ESCP, Estimating Product Performance Part 4 – Building Playgrounds & Fences”. Drug Development & Delivery June 2021 Vol 21 No 5, p. 40 (link to issue)
2020
2020 saw the publication of a three part series analyzing the development and approval times for pharmaceutical products approved by the U.S. FDA over the past decade. These articles are listed and linked below. Assignments for 2020 included an additional update to a major drug delivery and formulation report published in Drug Development & Delivery, analysis articles and reports, as well as numerous BioPharma articles and posts conceived, written, and produced for clients.
2020-01/02: “Drug Development Times, What it Takes – Part 1”, Drug Development & Delivery January/February 2020 Vol 20 No 1, p. 28 (link to issue)
2020-03: “Drug Development Times, What it Takes – Part 2”, Drug Development & Delivery March 2020 Vol 20 No 2, p. 56 (link to issue)
2020-04: “Drug Development Times, What it Takes – Part 3”, Drug Development & Delivery April 2020 Vol 20 No 3, p. 59 (link to issue)
2019
Assignments for 2019 included another update to a major drug delivery and formulation report published in Drug Development & Delivery, several of analysis articles as well as numerous BioPharma articles and posts conceived, written, and produced for clients.
2018
Assignments for 2018 like the year before included an updated major drug delivery and formulation report published in Drug Development & Delivery, a couple of analysis articles as well as numerous BioPharma articles and posts conceived, written, and produced for clients.
2017
Assignments for 2017 included an updated major drug delivery and formulation report published in Drug Development & Delivery, a couple of analysis articles as well as numerous BioPharma articles and posts conceived, written, and produced for clients.
2016
Assignments for 2016 included a major drug delivery and formulation report published in Drug Development & Delivery, a couple of analysis articles as well as numerous BioPharma articles and posts conceived, written, and produced for clients. (Information available upon request.)
2016-04: “Injectables: The New Oral?”, (Contract Pharma – April Issue) (link)
2016-07: “GLOBAL FORMULATION REPORT (2016) – Notable Technologies, Approvals, Transactions, Pipelines & Inflection Points”, (Drug Development and Delivery – July Issue) (link)
2016-11: “Two Strikes, Two Outs, or Time Out? Inhalation for Systemic Effect” (Contract Pharma -November Issue) (link)
2015
Assignments for 2015 include a major industry report published in a leading industry magazine as well as several dozen BioPharma related articles and posts conceived, written, and produced for clients. (Information available upon request.)
2015-07:
2014
2014-11: “Abuse Deterrent – What’s in the Pipeline?” (Drug Development & Delivery – November Issue). An examination of products and trends in the abuse deterrent market. Co-authored with T. Kararli and K. Sedo.
2011-05: “FIXED-DOSE COMBINATIONS – Fixed-Dose Combination Products – What’s in the Clinic? (Part 3 – Pipeline)” (Drug Development & Delivery – May 2014 Issue). Co-authored with T. Kararli and K. Sedo.
2014-04: “FIXED-DOSE COMBINATIONS – Fixed-Dose Combination Products – What’s in the Clinic? (Part 2 – Analysis)” (Drug Development & Delivery – April 2014 Issue). Co-authored with T. Kararli and K. Sedo.
2014-03: “FIXED-DOSE COMBINATIONS – Fixed-Dose Combination Products – What’s in the Clinic? (Part 1 – Introduction)” (Drug Development & Delivery – March 2014 Issue). Co-authored with T. Kararli and K. Sedo.
2011
2011-11: “The Pharma Revolution Recalibrated” (Pharmaceutical Executive – November 2011). Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars.
2011-10: “Generic DDEP Sales & Prescription Performance 2010” (Drug Development & Delivery – October 2011). This extends the September 2011 analysis and looks at generic drug delivery enhanced/enabled pharmaceuticals.
2011-09: “DDEP Sales & Prescription Performance 2010, Hints of the Future” (Drug Development & Delivery – September 2011 Issue). An examination of key trends that defined 2010 and how these figures may impact business going forward.
2011-06: “Numbers That Define the Business of Drug Delivery – 2011 Edition” (Drug Development & Delivery – June 2011 Issue). This article offers a peek at the numbers that define the business of Drug Delivery, which can provide a foundation to better plans and outcomes in the real world of drug delivery development and commercialization.
2011-05: “Two Questions for Drug Delivery” (Drug Development & Delivery – May 2011 Issue). Josef Bossart, PhD, raises debate about Drug Delivery’s role as a set of formulation technologies, a complement to the pharmaceutical industry toolbox, or as a business sector that develops technologies and products that provide for better therapeutic outcomes.
2011-04: “Drug Delivery: Products That Pop” (Drug Development & Delivery – April 2011 Issue). A brief look at drug delivery products that are special; in terms of therapeutic and commercial value.
2010 and Earlier
2010-11: “Decade in Review – Drug Delivery Transactions“, (Drug Delivery Technology Magazine – November/December 2010 Issue).
2010-10: “Decade in Review – Drug Delivery Company Performance“, (Drug Delivery Technology Magazine – October 2010 Issue).
2010-09: “Decade in Review – Drug Delivery Product Sales“, (Drug Delivery Technology Magazine – September 2010 Issue).
2010-06: “Oral Drug Delivery: The Numbers Behind the Business“, (ONdrugDELIVERY – June 2010 Issue).
2010-05: “Drug Delivery Products & Technologies, a Decade in Review: Approved Products 2000 to 2009“, (Drug Delivery Technology Magazine – May 2010 Issue).
2010-02: “Opening the Black Box“, (PMPS, Pharmaceutical Manufacturing and Packaging Sourcer (UK) – February 2010 Issue).
2010-01: “Product Development, Expectations & the Real World“, (Drug Delivery Technology Magazine – January 2010 Issue).
2009-07: “Up, Down, Sideways – A Look at Drug Delivery Strategy“, (Drug Delivery Technology – July 2009 Issue).
2009-02: “Drug Delivery Prospects for the Next Decade: An Informal Survey of Big Pharma“, (Drug Delivery Technology – February 2009 Issue).
2008-09: “Turning Insight into Action a Bionumbers Interview“, (Drug Delivery Technology – September 2008 Issue).
2008-03: “Addressing the Analgesic Gap in Breakthrough Cancer Pain“, (Drug Delivery Technology – March 2008 Issue).
2007-01: “Benchmarking Drug Delivery – Follow the Money“, (Drug Delivery Technology – January 2007 Issue).
2006-07: “Estimating the Value of Time in Biopharmaceutical Development” (Drug Delivery Technology – July 2006 Issue).
2006-06: “Parameters of Value – Drug Delivery Companies“, (Drug Delivery Technology – June 2006 Issue).
2006-03: “Benchmarking Drug Delivery – Updated Product Terms“, (Drug Delivery Technology – March 2006 Issue).
2006-01: “Benchmarking Drug Delivery – Business Development Resources“, (Drug Delivery Technology – January 2006 Issue).
2005-10: “Practices of Successful Partnering Companies – A Drug Delivery Perspective“, (Drug Delivery Technology – October 2005 Issue).
2005-06: “What Big Pharma Companies Wished Drug Delivery Companies Practiced“, (Drug Delivery Technology – June 2005 Issue).
2005-04: “Benchmarking Drug Delivery – Comparing Profit-Share & Royalty“, (Drug Delivery Technology – April 2005 Issue).
2005-03: “Benchmarking Drug Delivery – Defining the Potential of Drug Delivery“, (Drug Delivery Technology – March 2005 Issue).
2005-02: “Benchmarking Drug Delivery – Defining Product Benefit and Value“, (Drug Delivery Technology – February 2005 Issue).
2004-10: “Benchmarking Drug Delivery – Biotech & Drug Delivery Product Performance“, (Drug Delivery Technology – October 2004 Issue).
2004-09: “Benchmarking Drug Delivery – Product Terms“, (Drug Delivery Technology – September 2004 Issue).
2004-07: “Benchmarking Drug Delivery – Technology Royalty Rates“, (Drug Delivery Technology – July 2004 Issue).